Giocanti-Aurégan, Audrey http://orcid.org/0000-0002-7918-7845
Chbat, Elige
Darugar, Adil
Morel, Christophe
Morin, Bruno
Conrath, John
Devin, François
Funding for this research was provided by:
AVOPH
Article History
Received: 30 January 2017
Accepted: 23 January 2018
First Online: 1 February 2018
Ethics approval and consent to participate
: This study was conducted in accordance with the tenets of the Declaration of Helsinki, and an informed consent was obtained from subjects. Approval was obtained from the France Macula Federation ethical committee.
: An informed consent was obtained from the patient.
: Audrey Giocanti-Aurégan is consultant for Alimera, Allergan, Bayer and Novartis. Adil Darugar is consultant for Bayer and Novartis. Elige Chbat has nothing to disclose. François Devin, Christophe Morel, Bruno Morin are consultants for Alimera, Allergan, Bayer and Novartis, Roche, Ophtotec, Thea, Alcon, Zeiss. John Conrath is consultant for Alimera, Allergan, Bayer and Novartis, Roche, Ellex, Alcon.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.